Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: Originally issued on 05-May-2022 10:39:47. This version was issued on 05-May-2022 10:39:47

This alert has been issued to:
  • NHS Regional Offices
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive

  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Special Health Authorities
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive
  • DHSC Supply Disruption - Medicines

Action category: Action

Title: Baricitinib for Patients Hospitalised Due to COVID-19 (Adults and Children Aged 2 Years and Over)

Broadcast content:

Baricitinib (Olumiant) is now available as an additional treatment option for patients admitted to hospital to manage the symptoms of COVID pneumonia.   A patient may therefore now be given an IL-6 inhibitor (tocilizumab or sarilumab) after treatment with baricitinib has been commenced (or vice versa), according to clinical judgement.  Baricitinib should not be routinely co-administered (i.e. given simultaneously) with an IL-6 inhibitor. However, in the situation of illness requiring critical care support or where a patient has deteriorated despite treatment, clinical judgement may deem co-administration appropriate. The summary clinical guide, covering all of the routinely available COVID treatment options for patients admitted to hospital due to COVID, has been updated to include this additional treatment option.   Clinicians are encouraged to continue to proactively support recruitment into trials developing further evidence in the treatment of COVID-19. Patients admitted to hospital due to COVID may be considered for entry into the RECOVERY or REMAP-CAP trials. 

Additional information: This alert does not need to be cascaded to Primary Care

Alert reference: CEM/CMO/2022/007


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency